NASDAQ
44.63USD
-0.98 (-2.15%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.6B
P/E
—
EPS
—
Beta
0.54
52W range
35.51-59.68
Day range
44.35–45.67
Open
44.88
Prev close
45.61
Volume
573.6K
Avg volume
765.8K
Dividend
0.00
IPO
2012-05-01
https://www.globenewswire.com/news-release/2026/08/03/3337322/19871/en/Supernus-Announces-Second-Quarter-2026-Financial-Results.html · 8/3/2026+0.80
https://www.globenewswire.com/news-release/2026/08/03/3337311/19871/en/Supernus-Pharmaceuticals-and-Indivior-Pharmaceuticals-to-Merge-Creating-a-Diversified-CNS-Biopharmaceutical-Leader-with-Significant-Scale.html · 8/3/2026+0.80
https://seekingalpha.com/article/4903588-supernus-pharmaceuticals-inc-supn-presents-at-bank-of-america-global-healthcare-conference · 5/13/2026+0.10
https://www.prnewswire.com/news-releases/lunai-bioworks-inc-issues-letter-to-shareholders-302682738.html · 2/9/2026+0.60
https://www.fool.com/coverage/filings/2025/12/15/supernus-stock-is-up-31-this-past-year-but-still-20-below-2018-highs-as-one-fund-scales-back/ · 12/16/2025-0.20
https://www.globenewswire.com/news-release/2025/11/12/3186793/19871/en/Supernus-to-Participate-in-the-2025-Jefferies-Global-Healthcare-Conference-in-London.html · 11/12/2025+0.00
https://www.zacks.com/stock/news/2778790/bridgebio-pharma-bbio-soars-17-1-is-further-upside-left-in-the-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2778790 · 10/28/2025+0.00
https://www.zacks.com/stock/news/2753290/biogen-gets-eu-nod-for-first-postpartum-depression-drug?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2753290 · 9/18/2025+0.60
https://www.zacks.com/stock/news/2669902/supernus-pharmaceuticals-supn-surpasses-q2-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2669902 · 8/5/2025+0.80
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works